Jazz Pharmaceuticals (JAZZ) CEO receives 44,465 restricted stock units

Rhea-AI Filing Summary

GALA RENEE D reported acquisition or exercise transactions in this Form 4 filing.

Jazz Pharmaceuticals plc reported that President & CEO Renee D. Gala received an equity grant of 44,465 restricted stock units under the company’s 2011 Equity Incentive Plan. Each unit represents a right to receive one ordinary share when it vests.

The grant vests in four equal annual installments starting on March 5, 2026, with one-quarter vesting on the first anniversary of that date and the remaining three-quarters vesting in equal annual installments over the following three years. After this award, she directly holds 159,695 ordinary shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider GALA RENEE D

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	44,465	$0.00	--

Holdings After Transaction: Ordinary Shares — 159,695 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GALA RENEE D

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4 L2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	02/26/2026		A(1)		44,465	A	$0.0	159,695	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2026, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.

	By: /s/Paz Dizon, as attorney in fact For: Renee D. Gala	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Jazz Pharmaceuticals (JAZZ) CEO Renee Gala report on this Form 4?

Renee D. Gala reported receiving a grant of 44,465 restricted stock units. These units were awarded under Jazz Pharmaceuticals’ 2011 Equity Incentive Plan and will convert into ordinary shares only as they vest over time according to the defined schedule.

How many restricted stock units did the JAZZ CEO receive and at what price?

The CEO received 44,465 restricted stock units at a stated price of $0.00 per unit. This reflects an equity award rather than an open-market purchase, meaning no cash was paid by her for these units at the time of grant.

What is the vesting schedule for the 44,465 restricted stock units at Jazz Pharmaceuticals?

The 44,465 units vest in four equal annual installments starting March 5, 2026. One-quarter vests on the first anniversary of that date, with the remaining three-quarters vesting in equal annual installments over the following three years, subject to continued service.

How do these restricted stock units convert into Jazz Pharmaceuticals ordinary shares?

Each restricted stock unit represents a contingent right to receive one ordinary share upon vesting. As each tranche of units vests under the schedule, the corresponding number of ordinary shares is delivered, increasing the CEO’s directly held share count over time.

How many Jazz Pharmaceuticals shares does the CEO hold after this Form 4 transaction?

Following this equity award, Renee D. Gala is reported to directly own 159,695 ordinary shares. This figure reflects her direct ownership position after accounting for the newly granted restricted stock units disclosed in the Form 4 filing.

Under which plan were the JAZZ CEO’s restricted stock units granted?

The restricted stock units were granted under Jazz Pharmaceuticals’ 2011 Equity Incentive Plan. This plan is used to provide equity-based compensation, aligning executive interests with shareholders by delivering ordinary shares as awards vest over specified time periods.